title: CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.
abstract: Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cancer Research, was a stepping stone for subsequent research, leading to regulatory approval of bevacizumab for recurrent glioblastoma.
authors.affiliation: Department of Hematology/Oncology, University of Connecticut, Farmington, Connecticut. nam244@nyu.edu.
authors.forename: Nataliya
authors.initials: N
authors.lastname: Mar
authors.affiliation: Department of Neurology, Duke University, Durham, North Carolina.
authors.forename: Annick
authors.initials: A
authors.lastname: Desjardins
authors.affiliation: Department of Hematology/Oncology, Saint Francis Hospital, Hartford, Connecticut.
authors.forename: James J
authors.initials: JJ
authors.lastname: Vredenburgh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*